All In MedTech

FDA Clearance Tracker · P180025

MANTA Vascular Closure Device

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Feb 1, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Feb 1, 2019

Approved

Time to decision

207 days

Received Jul 9, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P180025
Device name
MANTA Vascular Closure Device
Applicant location
Morrisville, NC
Received
Jul 9, 2018
Decided
Feb 1, 2019
Decision
Approved
Supplements
14 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code MGB

FDA's approval statement

As written in FDA's record.

Approval for the 14F MANTA Vascular Closure Device. The device is indicated for closure of femoral arterial access sites following the use of 10-14F devices or sheaths (maximum OD/profile of 18F), and the 18F MANTA Vascular Closure Device is indicated for closure of femoral arterial access sites following the use of 15-18F devices or sheaths (maximum OD/profile of 25F).

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MGB. The earliest in FDA's data is P920004, decided Sep 29, 1995.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Teleflex Medical, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.